Перейти к содержимому
Bending the Curve Trial by Trial
?EN

Назад: Острый лимфобластный лейкоз у детей (ОЛЛ)

Список литературы: Острый лимфобластный лейкоз у детей (ОЛЛ)

105 источников, процитированных на этой странице. Ссылки ведут к первоисточнику.

  1. Farber S, Diamond LK, Mercer RD, Sylvester RF Jr, Wolff JA. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med. 1948;238(23):787-93. PubMedDOI
    ЦитироватьЗагрузка…
  2. BURCHENAL JH, MURPHY ML, ELLISON RR, SYKES MP, TAN TC, LEONE LA, et al. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood. 1953;8(11):965-99. PubMedDOI
    ЦитироватьЗагрузка…
  3. Frei E 3rd, Freireich EJ, Gehan E, Pinkel D, Holland JF, Selawry O, et al. Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate. Blood. 1961;18(4):431-54. DOI
    ЦитироватьЗагрузка…
  4. Frei E 3rd, Karon M, Levin RH, Freireich EJ, Taylor RJ, Hananian J, et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood. 1965;26(5):642-56. PubMedDOI
    ЦитироватьЗагрузка…
  5. Dolowy WC, Henson D, Cornet J, Sellin H. Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer. 1966;19(12):1813-9. PubMedDOI
    ЦитироватьЗагрузка…
  6. Hill JM, Roberts J, Loeb E, Khan A, MacLellan A, Hill RW. L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. JAMA. 1967;202(9):882-8. PubMedDOI
    ЦитироватьЗагрузка…
  7. Oettgen HF, Old LJ, Boyse EA, Campbell HA, Philips FS, Clarkson BD, et al. Inhibition of leukemias in man by L-asparaginase. Cancer Res. 1967;27(12):2619-31. PubMed
    ЦитироватьЗагрузка…
  8. George P, Hernandez K, Hustu O, Borella L, Holton C, Pinkel D. A study of "total therapy" of acute lymphocytic leukemia in children. J Pediatr. 1968;72(3):399-408. PubMedDOI
    ЦитироватьЗагрузка…
  9. Evans AE, Gilbert ES, Zandstra R. The increasing incidence of central nervous system leukemia in children. (Children's Cancer Study Group A). Cancer. 1970;26(2):404-9. PubMedDOI
    ЦитироватьЗагрузка…
  10. Aur RJ, Simone J, Hustu HO, Walters T, Borella L, Pratt C, et al. Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood. 1971;37(3):272-81. PubMedDOI
    ЦитироватьЗагрузка…
  11. Pinkel D. Five-year follow-up of "total therapy" of childhood lymphocytic leukemia. JAMA. 1971;216(4):648-52. PubMedDOI
    ЦитироватьЗагрузка…
  12. Pinkel D, Simone J, Hustu HO, Aur RJ. Nine years' experience with "total therapy" of childhood acute lymphocytic leukemia. Pediatrics. 1972;50(2):246-51. PubMedDOI
    ЦитироватьЗагрузка…
  13. Simone J, Aur RJ, Hustu HO, Pinkel D. "Total therapy" studies of acute lymphocytic leukemia in children. Current results and prospects for cure. Cancer. 1972;30(6):1488-94. PubMedDOI
    ЦитироватьЗагрузка…
  14. Elion GB. The purine path to chemotherapy. Science. 1989;244(4900):41-7. PubMedDOI
    ЦитироватьЗагрузка…
  15. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(1):18-24. PubMedDOI
    ЦитироватьЗагрузка…
  16. Cavé H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med. 1998;339(9):591-8. PubMedDOI
    ЦитироватьЗагрузка…
  17. Gaynon PS, Qu RP, Chappell RJ, Willoughby ML, Tubergen DG, Steinherz PG, et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group Experience. Cancer. 1998;82(7):1387-95. PubMedDOI
    ЦитироватьЗагрузка…
  18. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338(23):1663-71. PubMedDOI
    ЦитироватьЗагрузка…
  19. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet. 1999;354(9172):34-9. PubMedDOI
    ЦитироватьЗагрузка…
  20. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96(8):2691-6. PubMed
    ЦитироватьЗагрузка…
  21. European Medicines Agency. Glivec (imatinib): European public assessment report (EPAR) page. Marketing authorisation issued 07/11/2001; page last updated 12/11/2025. Page read 2026-10-20. Источник
  22. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003;101(10):3809-17. PubMedDOI
    ЦитироватьЗагрузка…
  23. US Food and Drug Administration. Approval letter, NDA 21-673, Clolar (clofarabine) intravenous infusion, Genzyme Corporation; accelerated approval, 28 December 2004. Источник
  24. Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005;23(15):3376-82. PubMedDOI
    ЦитироватьЗагрузка…
  25. US Food and Drug Administration. Approval letter, Arranon (nelarabine) injection, NDA 21-877, GlaxoSmithKline. Electronic signature date 28 October 2005. Источник
  26. Avramis VI, Tiwari PN. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine. 2006;1(3):241-54. PubMed
    ЦитироватьЗагрузка…
  27. European Medicines Agency. Sprycel (dasatinib): European public assessment report (EPAR) page. Marketing authorisation issued 20/11/2006; page last updated 02/10/2026. Page read 2026-10-20. Источник
  28. U.S. Food and Drug Administration. Approval letter, STN BL 103411/5052, pegaspargase (Oncaspar), supplement expanding the indication to first-line multi-agent treatment of acute lymphoblastic leukemia, 2006. Источник
  29. Miller DR. A tribute to Sidney Farber-- the father of modern chemotherapy. Br J Haematol. 2006;134(1):20-6. PubMedDOI
    ЦитироватьЗагрузка…
  30. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758-64. PubMedDOI
    ЦитироватьЗагрузка…
  31. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370(9583):240-250. PubMedDOI
    ЦитироватьЗагрузка…
  32. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008;111(12):5477-85. PubMedDOI
    ЦитироватьЗагрузка…
  33. Mody R, Li S, Dover DC, Sallan S, Leisenring W, Oeffinger KC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood. 2008;111(12):5515-23. PubMedDOI
    ЦитироватьЗагрузка…
  34. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470-80. PubMedDOI
    ЦитироватьЗагрузка…
  35. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26):2730-41. PubMedDOI
    ЦитироватьЗагрузка…
  36. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009;27(31):5175-81. PubMedDOI
    ЦитироватьЗагрузка…
  37. Aricò M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010;28(31):4755-61. PubMedDOI
    ЦитироватьЗагрузка…
  38. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206-14. PubMedDOI
    ЦитироватьЗагрузка…
  39. Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010;376(9757):2009-17. PubMedDOI
    ЦитироватьЗагрузка…
  40. Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 2012;13(9):936-45. PubMedDOI
    ЦитироватьЗагрузка…
  41. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012;30(14):1663-9. PubMedDOI
    ЦитироватьЗагрузка…
  42. Spain PD, Kadan-Lottick N. Observations of unprecedented remissions following novel treatment for acute leukemia in children in 1948. J R Soc Med. 2012;105(4):177-81. PubMedDOI
    ЦитироватьЗагрузка…
  43. US Food and Drug Administration. Supplement approval letter, Gleevec (imatinib mesylate) tablets, NDA 021588/S-037, Novartis Pharmaceuticals Corporation. Electronic signature date 25 January 2013. Источник
  44. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518. PubMedDOI
    ЦитироватьЗагрузка…
  45. Pui CH, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013;50(3):185-96. PubMedDOI
    ЦитироватьЗагрузка…
  46. Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14(3):199-209. PubMedDOI
    ЦитироватьЗагрузка…
  47. Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014;123(1):70-7. PubMedDOI
    ЦитироватьЗагрузка…
  48. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517. PubMedDOI
    ЦитироватьЗагрузка…
  49. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005-15. PubMedDOI
    ЦитироватьЗагрузка…
  50. Schultz KR, Carroll A, Heerema NA, Bowman WP, Aledo A, Slayton WB, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia. 2014;28(7):1467-71. PubMedDOI
    ЦитироватьЗагрузка…
  51. European Medicines Agency. Blincyto: EPAR page (conditional marketing authorisation 23 November 2015, standard authorisation 18 June 2018; page lists an update dated 22 September 2026). Accessed 20 October 2026. Источник
  52. Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16(16):1677-90. PubMedDOI
    ЦитироватьЗагрузка…
  53. US Food and Drug Administration. BLA 125557/S-005 and S-006 supplement approval letter, Blincyto (blinatumomab), Amgen; 30 August 2016. Источник
  54. Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, et al. Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. J Clin Oncol. 2016;34(20):2380-8. PubMedDOI
    ЦитироватьЗагрузка…
  55. von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2016;34(36):4381-4389. PubMedDOI
    ЦитироватьЗагрузка…
  56. European Medicines Agency. Besponsa: EPAR page (marketing authorisation issued 28 June 2017; page lists an update dated 18 May 2026). Accessed 20 October 2026. Источник
  57. US Food and Drug Administration. BLA 125557/S-008 supplement approval (replacement letter), Blincyto (blinatumomab), Amgen; effective date 11 July 2017 (letter signed 12 July 2017). 2017. Источник
  58. US Food and Drug Administration. BLA approval letter, STN 125646/0, tisagenlecleucel (Kymriah), Novartis Pharmaceuticals Corporation; 30 August 2017. Источник
  59. US Food and Drug Administration, Center for Biologics Evaluation and Research. Summary Basis for Regulatory Action, KYMRIAH (tisagenlecleucel), STN 125646/0; 30 August 2017. Источник
  60. Reshmi SC, Harvey RC, Roberts KG, Stonerock E, Smith A, Jenkins H, et al. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. Blood. 2017;129(25):3352-3361. PubMedDOI
    ЦитироватьЗагрузка…
  61. European Medicines Agency. Kymriah: EPAR page (marketing authorisation issued 23 August 2018; page lists an update dated 1 September 2026). Accessed 20 October 2026. Источник
  62. US Food and Drug Administration. BLA 125557/S-013 accelerated approval letter, Blincyto (blinatumomab), Amgen; 29 March 2018. Источник
  63. US Food and Drug Administration. Supplement approval letter, Sprycel (dasatinib) tablets, NDA 021986/S-021, Bristol-Myers Squibb Company. Electronic signature date 21 December 2018. Источник
  64. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-448. PubMedDOI
    ЦитироватьЗагрузка…
  65. Slayton WB, Schultz KR, Kairalla JA, Devidas M, Mi X, Pulsipher MA, et al. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol. 2018;36(22):2306-2314. PubMedDOI
    ЦитироватьЗагрузка…
  66. US Food and Drug Administration. Supplement approval letter (fulfillment of postmarketing requirement), Arranon (nelarabine) injection, NDA 021877/S-010, Novartis Pharmaceuticals Corporation. Electronic signature date 31 July 2019. Источник
  67. Jeha S, Pei D, Choi J, Cheng C, Sandlund JT, Coustan-Smith E, et al. Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. J Clin Oncol. 2019;37(35):3377-3391. PubMedDOI
    ЦитироватьЗагрузка…
  68. Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, et al. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. J Clin Oncol. 2019;37(25):2246-2256. PubMedDOI
    ЦитироватьЗагрузка…
  69. Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, et al. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020;38(28):3282-3293. PubMedDOI
    ЦитироватьЗагрузка…
  70. Shen S, Chen X, Cai J, Yu J, Gao J, Hu S, et al. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2020;6(3):358-366. PubMedDOI
    ЦитироватьЗагрузка…
  71. Angiolillo AL, Schore RJ, Kairalla JA, Devidas M, Rabin KR, Zweidler-McKay P, et al. Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. J Clin Oncol. 2021;39(13):1437-1447. PubMedDOI
    ЦитироватьЗагрузка…
  72. Brivio E, Locatelli F, Lopez-Yurda M, Malone A, Díaz-de-Heredia C, Bielorai B, et al. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood. 2021;137(12):1582-1590. PubMedDOI
    ЦитироватьЗагрузка…
  73. Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, et al. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021;325(9):833-842. PubMedDOI
    ЦитироватьЗагрузка…
  74. Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021;325(9):843-854. PubMedDOI
    ЦитироватьЗагрузка…
  75. Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J Clin Oncol. 2021;39(4):295-307. PubMedDOI
    ЦитироватьЗагрузка…
  76. US Food and Drug Administration. Supplement approval letter (fulfillment of postmarketing requirement), Clolar (clofarabine) injection, NDA 021673/S-027, Genzyme Corporation; electronic signature date 18 July 2022. Источник
  77. Moorman AV, Antony G, Wade R, Butler ER, Enshaei A, Harrison CJ, et al. Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial. J Clin Oncol. 2022;40(36):4228-4239. PubMedDOI
    ЦитироватьЗагрузка…
  78. O'Brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yuan CM, et al. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. J Clin Oncol. 2022;40(9):956-967. PubMedDOI
    ЦитироватьЗагрузка…
  79. US Food and Drug Administration. BLA Multidisciplinary Review and Evaluation, BLA 125557 S-023 and S-026, Blincyto (blinatumomab), Reference ID 5193267; review completion date 20 June 2023. Источник
  80. Hunger SP, Tran TH, Saha V, Devidas M, Valsecchi MG, Gastier-Foster JM, et al. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2023;10(7):e510-e520. PubMedDOI
    ЦитироватьЗагрузка…
  81. Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol. 2023;41(9):1664-1669. PubMedDOI
    ЦитироватьЗагрузка…
  82. van der Sluis IM, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, et al. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia. N Engl J Med. 2023;388(17):1572-1581. PubMedDOI
    ЦитироватьЗагрузка…
  83. US Food and Drug Administration. Besponsa (inotuzumab ozogamicin) prescribing information as approved with BLA 761040/S-003 (Reference ID 5341472); 6 March 2024. Источник
  84. US Food and Drug Administration. FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia. Notice, 6 March 2024. Источник
  85. US Food and Drug Administration. BLA 761040/S-003 supplement approval letter, Besponsa (inotuzumab ozogamicin), Wyeth Pharmaceuticals LLC; 6 March 2024. Источник
  86. US Food and Drug Administration. BLA 125557/S-028 supplement approval letter (corrected letter), Blincyto (blinatumomab), Amgen Inc.; electronic signature date 14 June 2024. Источник
  87. National Cancer Institute. Cancer in Children and Adolescents (fact sheet). Page updated 27 August 2024; accessed 20 October 2026. https://www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-fact-sheet Источник
  88. Rabin KR, Devidas M, Chen Z, Ji L, Kairalla J, Hitzler JK, et al. Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group. J Clin Oncol. 2024;42(2):218-227. PubMedDOI
    ЦитироватьЗагрузка…
  89. Kumar Upadhyay A, Prakash A, Kumar A, Jena S, Sinha N, Sharma S. Dr. Sidney Farber (1903-1973): Founder of Pediatric Pathology and the Father of Modern Chemotherapy. Cureus. 2024;16(8):e68286. PubMedDOI
    ЦитироватьЗагрузка…
  90. Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, et al. Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2025;392(9):875-891. PubMedDOI
    ЦитироватьЗагрузка…
  91. Inaba H, Teachey D, Annesley C, Batra S, Beck J, Colace S, et al. Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23(2):41-62. PubMedDOI
    ЦитироватьЗагрузка…
  92. ClinicalTrials.gov. NCT00549848 (Total Therapy Study XVI). Registry record, accessed 20 October 2026. NCT00549848
  93. ClinicalTrials.gov. NCT03007147 (AALL1631). Registry record, accessed 20 October 2026. NCT03007147
  94. ClinicalTrials.gov. NCT03959085 (AALL1732). Registry record, accessed 20 October 2026. NCT03959085
  95. ClinicalTrials.gov. NCT04307576 (ALLTogether1). Registry record, accessed 20 October 2026. NCT04307576
  96. ClinicalTrials.gov. NCT05327894 (Interfant-21). Registry record, accessed 20 October 2026. NCT05327894
  97. ClinicalTrials.gov. NCT07476729 (IntReALL BCP 2020). Registry record, accessed 20 October 2026. NCT07476729
  98. DuVall AS, McNeer J, Cheung MC, Adrianzen-Herrera DA, Advani A, Aljurf M, et al. American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults. Blood Adv. 2026;10(13):4671-4708. PubMedDOI
    ЦитироватьЗагрузка…
  99. U.S. Food and Drug Administration, Oncology Center of Excellence. Pediatric Oncology Drug Approvals (table current as of February 2026; page content current as of 03/03/2026). Accessed 2026-10-20. Источник
  100. US Food and Drug Administration. Verified Clinical Benefit | Cancer Accelerated Approvals. Oncology (Cancer)/Hematologic Malignancies Approval Notifications. Content current as of 16 October 2026. Источник
  101. O'Dwyer K, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, et al. American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults. Blood Adv. 2026;10(13):4726-4756. PubMedDOI
    ЦитироватьЗагрузка…
  102. Schrappe M, Locatelli F, Valsecchi MG, Zugmaier G, Vossen-Gajcy M, Starý J, et al. Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia. N Engl J Med. 2026;395(11):1075-1089. PubMedDOI
    ЦитироватьЗагрузка…
  103. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Leukemia - Acute Lymphocytic Leukemia (ALL). Page accessed 20 October 2026; the page displays no update date (its HTML metadata gives 22 April 2026). Источник
  104. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Childhood Leukemia (Ages 0-19). Page accessed 20 October 2026; the page displays no update date (its HTML metadata gives 22 April 2026). Источник
  105. Vieira Martins M, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, et al. Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics. J Clin Oncol. 2026;44(5):370-374. PubMedDOI
    ЦитироватьЗагрузка…